ライフサイエンスコーパス: granulocytopenia

1 uent grade 2 to 3 laboratory abnormality was granulocytopenia.

2 otherapy consisted primarily of grade 3 or 4 granulocytopenia.

3 fatigue, and transient thrombocytopenia and granulocytopenia.

4 tered at 2.4 mg/m(2), three had grade 3 or 4 granulocytopenia.

5 n sepsis induced circulating monocytosis and granulocytopenia.

6 m2, with six patients experiencing grade 3/4 granulocytopenia.

7 ctions in patients with sustained periods of granulocytopenia.

8 fatigue, and transient thrombocytopenia and granulocytopenia.

9 175 mg/m2 over 24 hours, despite predictable granulocytopenia.

10 with 54% of patients experiencing grade 3/4 granulocytopenia.

11 of the granulocyte nadir and the duration of granulocytopenia.

12 ominantly myelosuppression and in particular granulocytopenia.

13 s, the most common grade 3/4 events included granulocytopenia (1.8%), thrombocytopenia (1.4%), and hy

14 Grade III to IV toxic effects were granulocytopenia (14%), mucositis (20%), diarrhea (9%),

15 With the exception of granulocytopenia (25% v 13%), diarrhea (28% v 23%), and

16 usea and vomiting (45%), diarrhea (24%), and granulocytopenia (36%).

17 Grade 3 and 4 toxicities included granulocytopenia (36.1%), thrombocytopenia (8.3%), and n

18 ade 3 to 4 toxicities were leukopenia (49%), granulocytopenia (55%), and thrombocytopenia (22%).

19 ide effects were stomatitis 15%, anemia 14%, granulocytopenia 6%, and thrombocytopenia 6%.

20 was the most frequent toxicity: grade 3 or 4 granulocytopenia, 70% of patients in Arm A and 78% in Ar

21 s associated with more grade 3/4 neutropenia/granulocytopenia and febrile neutropenia than XELOX, and

22 Toxicity was moderate, with granulocytopenia and neurotoxicity being the most common

23 addition, TNFR5-G1,3 treatment shortened the granulocytopenia and reduced the loss of cellular TNF re

24 imulating factor [G-CSF]) on the duration of granulocytopenia and thrombocytopenia after intensive co

25 for minimally pretreated patients, and both granulocytopenia and thrombocytopenia for heavily pretre

26 Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 70%

27 Grade 3 to 4 granulocytopenia and thrombocytopenia occurred after 76%

28 During chemotherapy cycles 4 to 5, grade 4 granulocytopenia and thrombocytopenia were noted in 43%

29 Grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 4

30 Grade 4 granulocytopenia and thrombocytopenia were observed in 5

31 d significantly higher grades of leukopenia, granulocytopenia, and thrombocytopenia, as well as liver

32 ined fever after probable exposure to ticks, granulocytopenia, and thrombocytopenia.

33 )-dose level, two patients exhibited grade 3 granulocytopenia, and two patients had grade 3 anemia.

34 8%, respectively, and consisted primarily of granulocytopenia, anemia, and neuropathy.

35 he risk of clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction

36 Severe granulocytopenia developed in 43% of patients and thromb

37 argeted deletion of PLSCR1 display perinatal granulocytopenia due to defective response of hematopoie

38 ductions in the degree or duration of severe granulocytopenia following intensive multiagent chemothe

39 The DLT of this DX-8951f schedule was granulocytopenia for minimally pretreated patients, and

40 Granulocytopenia frequently occurs in alcohol abusers wi

41 M-CSF reduced the median duration of grade 4 granulocytopenia from 9.0 days (range, 2 to 24) to 7.0 d

42 herapy would reduce the duration of absolute granulocytopenia further while initiating sustained long

43 The major toxicity was granulocytopenia (grade 3 to 4), which occurred in virtu

44 Myelotoxicities included grade > or = 3 granulocytopenia in 23% and thrombocytopenia in 6% of 11

45 Major toxic effects included grade 4 granulocytopenia in 34 (55%), grade 4 thrombocytopenia i

46 experienced with ITP included grade 3 and 4 granulocytopenia in four patients and grade 3 nausea/vom

47 G-CSF markedly shortened the duration of granulocytopenia in patients with AML receiving intensiv

48 ere was a marked decrease in the duration of granulocytopenia less than 500/microL in two groups of p

49 st common toxicities were anemia, leukopenia/granulocytopenia, malaise/fatigue, nausea/vomiting, alop

50 The most common side effects were granulocytopenia, nausea, and nonneutropenic fever.

51 During induction chemotherapy, grade 3/4 granulocytopenia occurred in 32% and 38% of patients on

52 Grade 3 or 4 granulocytopenia occurred in 5% of EU/5-FU patients and

53 With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and

54 analysis of CPA-induced myelosuppression and granulocytopenia showed that at high doses (> or =100 mg

55 Grade 3 and 4 toxic effects included granulocytopenia, stomatitis, diarrhea, rash, nausea, an

56 e pretreated with cyclophosphamide to induce granulocytopenia, there was a variable increase in total

57 tients having grade 3 and 30% having grade 4 granulocytopenia; there were no episodes of febrile neut

58 nd only 6%, 3%, and 3% of patients developed granulocytopenia, thrombocytopenia, and neutropenic seps

59 y on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I).

60 Granulocytopenia was associated with impaired host defen

61 Significant granulocytopenia was common, but significant thrombocyto

62 Grade 4 granulocytopenia was more common in arm 1 (79% v 54%; P

63 At doses higher than 2.4 mg/m(2), DLT granulocytopenia was observed.

64 Granulocytopenia was significantly less for EM-V compare

65 Grade 4 or 5 granulocytopenia was the only common serious toxicity, a

66 The major toxicity was granulocytopenia with grade 3 or better occurring in 40

67 he dose-limiting toxicity of vinorelbine was granulocytopenia, with 54% of patients experiencing grad

68 Granulocytopenia without fever and grade 2/3 neurotoxici